The last few years have seen a resurgence of interest in inhibitors of monoamine oxidase [MAO, EC 1.4.3.4 , amine oxidase (flavin-containing)] and also of coppercontaining amine oxidases (EC 1.4.3.6 ). This has largely been stimulated by the discovery of multiple forms of these enzymes. In the case of MAO, two forms have been identified and designated type A (clorgyline-sensitive; Johnston, 1968) and type B (L-deprenyl-sensitive; Knoll & Magyar, 1972) . Likewise, multiple forms of Cu2+-dependent amine oxidases exist (Blaschko, 1974) . Although many hundreds of M A 0 inhibitors have been synthesized and several inhibitors of the Cu2+ -dependent amine oxidases are known, very few have been designed rationally. Furthermore, most compounds show little selectivity for the different enzyme forms. We describe here the approach we have used to develop suicide substrates which show selectivity for these different amine oxidases. 
General concept
If the oxidative deamination of a substrate by an amine oxidase can be described by Scheme 1, then the corresponding B-halomethylene analogues would be predicted to act as suicide substrates (Scheme 2) leading to irreversible inactivation. An indication that this approach would be tenable came from the work of Rando (1 973), who used chloro-and bromo-allylamines to weakly but irreversibly inhibit MAO. We speculated that fluoroallylamines might have a higher affinity for the enzyme and that substitution on the aromatic ring might alter, in a manner analogous to the natural substrates, the selectivity for the different enzyme forms.
MAO-B-selective inhibitors
As shown by McDonald et al. (1985) , 8-fluoromethylene analogues are considerably more potent than effect when administered as adjunct therapy with a combination of L-dihydroxyphenylalanine (L-DOPA) and an inhibitor of the peripheral aromatic L-amino acid decarboxylase (AADC) (Rinne, 1983) . (E)-2-(3,4-Dimethoxyphenyl)-3-fluoroallylamine (MDL 72 149, the most extensively studied of these new inhibitors, differs from L-deprenyl in not being metabolized to amphetamine, having no action on monoamine uptake and release, and being devoid of effects on drug-metabolizing enzymes of the liver (Bey et al., 1984b; Fozard et al., 1984 Fozard et al., , 1985a Zreika et al., 1984) . However, like L-deprenyl, MDL 72145 does potentiate the central effects of L-DOPA without augmenting its peripheral cardiovascular effects Fozard et al.,. 19856 ) and with little propensity for causing adverse interactions with tyramine (Fozard et al., 1985a) , indicating its potential utility in Parkinson's disease (Fozard et al., 1985a,b) . Moreover, in experimental animals, MDL 72145 is, like L-deprenyl, able to prevent the neurotoxic effect of Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine, which produces Parkinsonian-like effects in man (Heikkela et al., 1984; Bradbury et al., 1985; Youdim et al., 1985) . the corresponding bromo-or chloro-methylene derivatives as inhibitors of MAO, having affinities in the nanomolar range. These inhibitors display the kinetic characteristics of enzyme-activated irreversible inhibition (Bey et al., 1984a; Zreika et al., 1984; McDonald et al., 1985) . As can be seen from Table 1 , there is a relationship between the structure of the inhibitor and the natural substrate in terms of selectivity for the A and B forms of MAO.
Further development of this series involving elongation of the side chain and introduction of heteroatoms has led to compounds with even greater selectivity for the MAO-B enzyme. Of particular interest is (2)-2-(2,4-dichlorophenoxy)methyl-3-fluoroallylamine (MDL 72638), 72638), which, although a structural analogue of the selective MAO-A inhibitor, clorgyline, shows surprising potency and selectivity for the B-form of the enzyme (McDonald et al., 1986) . Likewise, (2)-2-(phenylthiomethyl)-3-fluoroallylamine (MDL 72887) has a greater than 1000-fold selectivity for the MAO-B enzyme in vitro and is the most selective MAO-B inhibitor in vivo we have found to date. Its respective oral ED,, values for the A and B enzymes of rat brain are 25 and 0.35mg/kg. For comparison, L-deprenyl given orally to rats inhibits brain MAO-A by 50% at 80mg/kg and MAO-B at 4.8mg/kg (Fozard et al., 1985a) . In view of the relationship that exists between the simple phenylethylamine substrates and the corresponding inhibitor in terms of selectivity for the enzyme type it might be predicted that the substrate corresponding to MDL 72887, i.e. phenylthiopropylamine, would be selectively deaminated by the B-form of MAO. This remains to be tested.
With the 50 haloallylamine derivatives we have synthesized having different selectivities and potencies for the two forms of MAO, it is hoped that the use of computer graphics will enable us to probe and possibly map the active site(s) of the two enzyme forms. Before this is possible, however, it will be necessary to establish to which nucleophile of the apoenzyme or of its flavin cofactor irreversible binding takes place.
These new and selective inhibitors of MAO-B have a potential utility in Parkinson's disease, since there is now considerable evidence that L-deprenyl has a beneficial Vol. 14 Site-selective M A 0 inhibition M A 0 inhibitors have been shown to be effective antidepressants (Quitkin et al., 1979) . Nevertheless, they are seldom used in the clinic due to the risk of dangerous interactions with tyramine-containing foods, the so called 'cheese effect' (Blackwell, 1963) . If it can be assumed that the therapeutic effect of M A 0 inhibitors arises through inhibition of monoamine metabolism in the central nervous system and that the interactions with tyramine occur in the periphery, then the ideal inhibitor would be one that acted exclusively in the brain. The relationship of the fluoroallylamine inhibitors to the natural monoamine neurotransmitters suggested a way of achieving this objective. Based on the fact that L-DOPA is decarboxylated to dopamine by AADC and is used in the clinic in combination with a peripherally selective inhibitor of AADC to restrict dopamine formation to the brain (Marsden et al., 1973) , and that likewise, m-tyrosine is an excellent substrate of AADC (Boulton & Juorio, 1983) , we theorized that the corresponding amino acid containing the latent functional B-halomethylene group would be a suitable candidate. In practice the corresponding (E)-B-fluoromethylene-m-tyrosine (MDL 72394) is readily decarboxylated by AADC both in vitro (Palfreyman et al., 1983 McDonald et al., 1984) and in vivo to yield the potent irreversible M A 0 inhibitor (E)-B-fluoromethylene-mtyramine (MDL 72392). Co-administration with carbidopa or low doses of the enzyme-activated irreversible inhibitor of AADC, a-monofluoromethyldopa Palfreyman et al., 1979) , restricts M A 0 inhibition to the brain and in this way significantly reduces the propensity of the treated animals to react adversely in the periphery with tyramine (Palfreyman et al., 1983 Jung et al., 1985) .
There are other potential advantages to the concept. Thus, due to the distribution of AADC predominantly within monoamine nerves of the brain, inhibition after administration of MDL 72394 is directed both to the sites and to the enzyme most relevant to the proposed clinical utilization (Mely et al., 1984a, b; Palfreyman et al., 1985; Sleight et al., 1985) . Furthermore, the structural analogy of MDL 72394 with L-tyrosine makes the former compound a suitable substrate for the amino acid transport system from the blood to the brain . This property, together with the neuronal selectivity, probably explains the impressive potency of this new M A 0 inhibitor. Doses as low as 15 pg/kg (orally) iven daily for 5 days in combination with carbidopa P 10 mg/kg, orally) produce substantial inhibition of rat brain M A 0 (Palfreyman et al., 1983) . This new type of dual enzyme-activated irreversible inhibitor cannot be considered only in terms of being MAO-A or MAO-B selective in the same way as other M A 0 inhibitors because the active amine moiety will be selectively formed in the body in tissues with high AADC activity. Within the brain, this will occur predominantly in monoamine-containing nerves. For this reason we prefer the term site-selective rather than MAO-A or MAO-B selective as the case may be.
It remains to be seen if this novel approach to obtaining brain-selective inhibition of M A 0 represents an improvement over existing therapies in the treatment of depression. But if the data obtained in animal studies are a guideline then such an inhibitor should be largely free of the 'cheese reaction', the major drawback associated with the therapeutic use of this class of compound.
Cd' -containing amine oxidase inhibitors
The work of Neumann et al. (1975) suggested that certain B-haloallylamines could be expected to inhibit the second class of amine oxidases characterized by containing copper (Blaschko, 1974) in a manner analogous to the inactivation of the flavin-containing monoamine oxidases. One might predict that suitable structural modifications of the molecule to exploit the substrate specificity of the different enzymes in this class should produce the necessary selectivity of action. We were interested in developing a selective inhibitor for the benzylamine oxidase enzyme of vascular tissue (Lewinsohn, 1981) . This enzyme, also known as semi-carbazide-sensitive amine oxidase (SSAO; see Barrand et al., 1984) or clorgylineresistant amine oxidase (see Lyles & Callingham, 1975) , has no known physiological function and the development of a selective inhibitor might be expected greatly to facilitate definition of such a r61e.
Initial experiments confirmed that the fluoroallylamine, MDL 72145, was a time-dependent irreversible inhibitor of rat aorta SSAO, showing marked activity at a concentration of the order of lOmM (Lyles & an inhibitor of MAO-A and MAO-B. Furthermore, MDL 72145 is also a potent inhibitor of MAO-B. We had previously shown that substituted P-chloroallylamines were much weaker inhibitors of M A 0 than the corresponding fluoroallylamine derivatives. To our surprise, (E)-/3-phenyl-3-chloroallylamine (MDL 72274) proved a potent time-dependent, irreversible inhibitor of SSAO being some 65000-and 1500-fold respectively more potent in this respect than as an inhibitor of MAO-A and MAO-B. Furthermore, MDL 72274 inhibits diamine oxidase of hog kidney only at millimolar concentrations. When administered to rats, MDL 72274 (0.1-50 mg/kg, intraperitoneally) produced potent dose-and time-related inhibition of lung and aorta SSAO. For example, at 2 mg/kg intraperitoneally, SSAO was inhibited by 70 and 90% in the lungs and aorta 6 h after treatment and there was no inhibitory effect on MAO-A or MAO-B in brain, heart and liver. This selective inhibitor of SSAO should prove indispensible in exploring the functional r61e of this enzyme, which has particularly high activity in the vascular smooth muscle of animals and man.
Conclusions
The examples described show the potential of designing suicide substrates of two classes of amine oxidases that are susceptible to alkylation by B-halomethylene derivatives of selective substrates. Since there are several other amine oxidases that could be important targets for drug design the potential of this approach offers exciting prospects for the future development of selective suicide substrates.
